GGrantIndex
← Search

Technologies to Advance Next Generation Anthrax Vaccines

$762,432N01FY2016AINIH

Center For Expermental Software Engr Md, Riverdale MD

Investigators

Abstract

The scope of product development activities that may be addressed through this award span manufacturing and formulation process development through clinical studies, including: manufacturing, characterization and release of pilot lot cGMP material; vaccine stability testing ; conduct of non-clinical studies, e.g., Investigational New Drug (IND)-enabling toxicology studies; development, qualification and, where necessary, validation of all assays and reagents needed to support product development; and the delivery to the NIAID of 2000 doses of cGMP bulk drug substance as well as 2000 doses of cGMP final container candidate.

View original record on NIH RePORTER →